Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORADIL vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Long-term maintenance treatment of asthma,Prevention of exercise-induced bronchospasm,Maintenance treatment of chronic obstructive pulmonary disease (COPD)
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Metabolized primarily by hepatic glucuronidation and to a lesser extent by CYP2D6, CYP2C19, and CYP2C9.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
61% bound to plasma proteins, primarily albumin.
85-90% bound to albumin.
6.0 L/kg (extensive tissue distribution, indicating high penetration into lungs and peripheral tissues).
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Inhalation: ~30% (systemic absorption from lungs; oral bioavailability negligible due to first-pass metabolism).
Oral: 60-80% (first-pass metabolism reduces bioavailability).
No dose adjustment required for renal impairment.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
No specific dose adjustment recommended; use caution in severe hepatic impairment.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Children 5 years and older: 12 mcg inhalation twice daily. No dosing established for children under 5 years.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
No specific dose adjustment; monitor for adverse effects due to potential comorbidities.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
LABAs increase the risk of asthma-related death; Foradil should only be used in patients with asthma not adequately controlled on asthma controller medications or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
No FDA boxed warning exists for this combination product.
Increased risk of asthma-related death,Deterioration of disease and acute episodes may occur and should be treated with a short-acting beta2-agonist,Cardiovascular effects (increased heart rate, blood pressure, ECG changes),Hypokalemia and hyperglycemia may occur,Paradoxical bronchospasm may occur and require immediate discontinuation,Do not use with other LABAs
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to formoterol or any ingredient in the formulation,Use as monotherapy in asthma without concomitant inhaled corticosteroid,Treatment of acute asthma symptoms or exacerbations
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
No specific food interactions. Grapefruit/grapefruit juice may increase systemic exposure via CYP3A4 inhibition; avoid concurrent use.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal loss, decreased fetal weight, and skeletal variations. There are no adequate and well-controlled studies in pregnant women. During first trimester, risk cannot be ruled out. Second and third trimesters: potential risk of maternal beta-agonist effects causing uterine relaxation and delayed labor. Use only if potential benefit justifies potential risk to fetus.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Formoterol is excreted in human milk in small amounts. M/P ratio not established. Caution should be exercised when administered to nursing women. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for FORADIL and any potential adverse effects on the breastfed infant from the drug or underlying maternal condition.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
No specific dose adjustments are recommended for FORADIL during pregnancy based on pharmacokinetic changes. However, use the lowest effective dose to control asthma symptoms. Monitor for potential increased need for rescue medication due to pregnancy-related changes in asthma severity. No data indicate significant pharmacokinetic changes requiring dosing modification.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
FORADIL (formoterol fumarate) is a long-acting beta2-agonist (LABA) indicated for maintenance treatment of asthma and COPD, but must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Onset of bronchodilation occurs within 5-10 minutes, peaking at 1-3 hours, with duration up to 12 hours. Not for acute bronchospasm. Risk of paradoxical bronchospasm; discontinue if occurs. Monitor for increased heart rate, blood pressure, and QTc prolongation. Caution in patients with cardiovascular disorders, seizure disorders, thyrotoxicosis, or diabetes.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Use FORADIL exactly as prescribed; do not use to relieve sudden breathing problems.,Always have a fast-acting rescue inhaler (e.g., albuterol) for acute symptoms.,Do not use more than 2 inhalations every 12 hours; maximum daily dose is 48 mcg.,Rinse mouth with water after each use to reduce risk of thrush (if using with ICS).,Seek medical help immediately if breathing worsens, chest tightness, or hives develop.,Inform your doctor if you have heart disease, high blood pressure, seizures, thyroid problems, or diabetes.,Store capsules in blister pack, use only with provided Aerolizer inhaler; do not swallow capsules.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORADIL vs ACCURBRON, answered by our medical review team.
FORADIL is a Bronchodilator that works by Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORADIL and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORADIL is: Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORADIL and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORADIL is classified as Category C. FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.